{"id":5825,"date":"2012-10-15T11:53:00","date_gmt":"2012-10-15T11:53:00","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=5825"},"modified":"2021-08-24T01:43:43","modified_gmt":"2021-08-24T01:43:43","slug":"aspirin-and-ovarian-cancer-study","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/aspirin-and-ovarian-cancer-study\/","title":{"rendered":"Aspirin and Ovarian Cancer study"},"content":{"rendered":"\r\n<h2 class=\"wp-block-heading\">Further support for a randomised clinical trial of aspirin, Oncologist says<\/h2>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>New research published in <a href=\"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1600-0412.2012.01472.x\" target=\"_blank\" rel=\"noreferrer noopener\">Acta Obstetricia et Gynecologica Scandinavica<\/a>, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, showed regular aspirin <em>may<\/em> decrease the risk of ovarian cancer.<\/p>\r\n\r\n\r\n\r\n<p>Ovarian Cancer is the ninth most common cancer in women, of which 1\/3 are serious adenocarcinomas. In Australia, over 60% of diagnosed ovarian cancers are in women aged over 60.<\/p>\r\n\r\n\r\n\r\n<p>\u201cThis study of 1,564 women aged between 35 and 79, suggested a possible benefit, however it was not a statistically significant reduction in ovarian cancer,\u201d said Medical Oncologist, Dr Andrew Haydon, who <strong><a href=\"\/aus\/about-us\/\">works<\/a><\/strong> on the cancer aspect of the ASPREE (<strong>ASP<\/strong>irin in\u00a0<strong>R<\/strong>educing\u00a0<strong>E<\/strong>vents in the\u00a0<strong>E<\/strong>lderly) trial.<\/p>\r\n\r\n\r\n\r\n<p>\u201cThis was also a relatively small study that did not show a relationship between the dose and duration of aspirin use and the reduced risk of cancer. In longer use (beyond five years) the risk may be reversed,\u201d he said.<\/p>\r\n\r\n\r\n\r\n<p>The number of cases of ovarian cancer in Australia is increasing \u2013 women over the age of 70 have the highest incidence \u2013 primarily due to an ageing and growing population.<\/p>\r\n\r\n\r\n\r\n<div class=\"wp-block-image\">\r\n<figure class=\"alignleft size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"300\" height=\"300\" class=\"wp-image-5719\" src=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/03\/Andrew-Haydon-SMICS-Clinical-Director_square_correct-dimensions-300x300-1.jpg\" alt=\"White male with a shaved head and an open pale blue shirt and navy jacket in front of a grey\/blue background\" \/>\r\n<figcaption><em>Above: Dr Andrew Haydon is an investigator working on cancer aspects of the ASPREE trial.<\/em><\/figcaption>\r\n<\/figure>\r\n<\/div>\r\n\r\n\r\n\r\n<p>\u201cWhile this study is interesting, it supports large randomised studies such as ASPREE to provide more robust evidence relevant to older Australian women,\u201d said Dr Haydon.<\/p>\r\n\r\n\r\n\r\n<p>\u201cASPREE will also weigh any potential benefits versus the potential risks, such as bleeding.\u201d<\/p>\r\n\r\n\r\n\r\n<p><em>Updated April 1, 2021<\/em><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Oncologist Dr Andrew Haydon, says a recent study on aspirin and ovarian cancer supports the need for a large randomised aspirin trial.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,18,16],"tags":[28,47],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5825"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=5825"}],"version-history":[{"count":10,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5825\/revisions"}],"predecessor-version":[{"id":8545,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5825\/revisions\/8545"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=5825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=5825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=5825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}